These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 34357480

  • 1. A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study.
    Vitetta L, Butcher B, Henson JD, Rutolo D, Hall S.
    Inflammopharmacology; 2021 Oct; 29(5):1361-1370. PubMed ID: 34357480
    [Abstract] [Full Text] [Related]

  • 2. Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
    Clarke S, Butcher BE, McLachlan AJ, Henson JD, Rutolo D, Hall S, Vitetta L.
    PLoS One; 2022 Oct; 17(10):e0270543. PubMed ID: 36240167
    [Abstract] [Full Text] [Related]

  • 3. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G.
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [Abstract] [Full Text] [Related]

  • 4. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D, Butler J, Ong K, Nguyen TH, Cox S, Francis B, Mcintosh M, Lilley B.
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [Abstract] [Full Text] [Related]

  • 5. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM.
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers.
    Hosseini A, McLachlan AJ, Lickliter JD.
    Br J Clin Pharmacol; 2021 Apr; 87(4):2070-2077. PubMed ID: 33075170
    [Abstract] [Full Text] [Related]

  • 7. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
    Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H.
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):751-758. PubMed ID: 29125702
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults.
    Hobbs JM, Vazquez AR, Remijan ND, Trotter RE, McMillan TV, Freedman KE, Wei Y, Woelfel KA, Arnold OR, Wolfe LM, Johnson SA, Weir TL.
    Phytother Res; 2020 Jul; 34(7):1696-1703. PubMed ID: 32147925
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses.
    Ryan D, McKemie DS, Kass PH, Puschner B, Knych HK.
    Drug Test Anal; 2021 Jul; 13(7):1305-1317. PubMed ID: 33723919
    [Abstract] [Full Text] [Related]

  • 13. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
    Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G.
    Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.
    Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A.
    Eur J Pharm Biopharm; 2020 Sep; 154():108-115. PubMed ID: 32634571
    [Abstract] [Full Text] [Related]

  • 15. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG, White L, Wright S, Wilbraham D, Guy GW.
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [Abstract] [Full Text] [Related]

  • 16. Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies.
    Provenzano R, De Caro C, Vitiello A, Izzo L, Ritieni A, Ungaro F, Quaglia F, Russo E, Miro A, d'Angelo I.
    Drug Deliv Transl Res; 2024 Jun; 14(6):1648-1659. PubMed ID: 38064145
    [Abstract] [Full Text] [Related]

  • 17. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
    Cherniakov I, Izgelov D, Domb AJ, Hoffman A.
    Eur J Pharm Sci; 2017 Nov 15; 109():21-30. PubMed ID: 28736128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sex Differences in the Pharmacokinetics of Cannabidiol and Metabolites Following Oral Administration of a Cannabidiol-Dominant Cannabis Oil in Healthy Adults.
    MacNair L, Kulpa J, Hill ML, Eglit GML, Mosesova I, Bonn-Miller MO, Peters EN.
    Cannabis Cannabinoid Res; 2024 Aug 15; 9(4):e1170-e1178. PubMed ID: 37267269
    [Abstract] [Full Text] [Related]

  • 20. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
    Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb 15; 269(1):17-35. PubMed ID: 30661105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.